Welcome!

News Feed Item

Tremor Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Tremor Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312347/Tremor-Global-Clinical-Trials-Review-H2-2014.html

Tremor Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Tremor Global Clinical Trials Review, H2, 2014" provides data on the Tremor clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tremor. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tremor. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Tremor 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Tremor to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Tremor to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17

In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Tremor 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Tremor Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Veloxis Pharmaceuticals A/S 27
Clinical Trial Overview of Veloxis Pharmaceuticals A/S 27
Clinical Trial Overview of Top Institutes / Government 28
University of Alabama at Birmingham 28
Clinical Trial Overview of University of Alabama at Birmingham 28
National Institute of Neurological Disorders and Stroke 29
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 29
Boston Children's Hospital 30
Clinical Trial Overview of Boston Children's Hospital 30
Ohio State University 31

Clinical Trial Overview of Ohio State University 31
Emory University 32
Clinical Trial Overview of Emory University 32
Mayo Clinic 33
Clinical Trial Overview of Mayo Clinic 33
Syracuse University 34
Clinical Trial Overview of Syracuse University 34
Yazd Medical University 35
Clinical Trial Overview of Yazd Medical University 35
Mount Sinai Hospital 36
Clinical Trial Overview of Mount Sinai Hospital 36
University of California, Davis 37
Clinical Trial Overview of University of California, Davis 37
Five Key Clinical Profiles 38
Appendix 59
Abbreviations 59
Definitions 59
Research Methodology 60
Secondary Research 60
About GlobalData 61
Contact Us 61
Disclaimer 61
Source 61

List of Tables
Tremor Therapeutics, Global, Clinical Trials by Region, 2014* 6
Tremor Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Tremor Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Tremor Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Tremor Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Tremor Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Tremor Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12
Proportion of Tremor to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Tremor Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Tremor Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Tremor to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Tremor Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Tremor Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Tremor Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Tremor Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Tremor Therapeutics, Global, Terminated Clinical Trials, 2014* 21
Tremor Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Tremor Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Tremor Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Tremor Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 25
Tremor Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 26
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Veloxis Pharmaceuticals A/S, 2014* 27
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alabama at Birmingham, 2014* 28
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 29
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Boston Children's Hospital, 2014* 30

Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University, 2014* 31
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 32
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 33
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Syracuse University, 2014* 34
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Yazd Medical University, 2014* 35
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by Mount Sinai Hospital, 2014* 36
Tremor Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Davis, 2014* 37

List of Figures
Tremor Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Tremor Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Tremor Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Tremor Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9

Proportion of Tremor to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Tremor Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Tremor Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Tremor to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Tremor Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Tremor Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Tremor Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Tremor Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Tremor Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Tremor Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
Tremor Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Tremor Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 26
GlobalData Methodology 60

Read the full report:
Tremor Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312347/Tremor-Global-Clinical-Trials-Review-H2-

2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com  
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, will introduce two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a...
Any startup has to have a clear go –to-market strategy from the beginning. Similarly, any data science project has to have a go to production strategy from its first days, so it could go beyond proof-of-concept. Machine learning and artificial intelligence in production would result in hundreds of training pipelines and machine learning models that are continuously revised by teams of data scientists and seamlessly connected with web applications for tenants and users.
IT organizations are moving to the cloud in hopes to approve efficiency, increase agility and save money. Migrating workloads might seem like a simple task, but what many businesses don’t realize is that application migration criteria differs across organizations, making it difficult for architects to arrive at an accurate TCO number. In his session at 21st Cloud Expo, Joe Kinsella, CTO of CloudHealth Technologies, will offer a systematic approach to understanding the TCO of a cloud application...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Secure Channels, a cybersecurity firm, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Secure Channels, Inc. offers several products and solutions to its many clients, helping them protect critical data from being compromised and access to computer networks from the unauthorized. The company develops comprehensive data encryption security strategie...
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyer belt between the Software Factory and production stages. Artifacts are m...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Cloud resources, although available in abundance, are inherently volatile. For transactional computing, like ERP and most enterprise software, this is a challenge as transactional integrity and data fidelity is paramount – making it a challenge to create cloud native applications while relying on RDBMS. In his session at 21st Cloud Expo, Claus Jepsen, Chief Architect and Head of Innovation Labs at Unit4, will explore that in order to create distributed and scalable solutions ensuring high availa...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...